𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Activity of antibodies to hepatitis C virus of patients with chronic non-A, non-B hepatitis decreases during interferon α therapy

✍ Scribed by Yoshioka, Kentaro ;Kakumu, Shinichi ;Hayashi, Hisao ;Shinagawa, Tadashi ;Wakita, Takaji ;Ishikawa, Tetsuya ;Itoh, Yuji ;Takayanagi, Masahiro

Publisher
Springer-Verlag
Year
1991
Tongue
English
Weight
202 KB
Volume
26
Category
Article
ISSN
0435-1339

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hepatitis C viraemia rebound after “succ
Hepatitis C viraemia rebound after “successful” interferon therapy in patients with chronic non-A, non-B hepatitis
✍ Dr. J. A. Garson; S. Brillanti; C. Ring; P. Perini; M. Miglioli; L. Barbara 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 449 KB 👁 1 views

## Abstract A quantitative polymerase chain reaction (PCR) assay for hepatitis C viral RNA (HCV‐RNA) was used to monitor viraemia levels in six patients at multiple time points before, during, and after interferon therapy for chronic non‐A, non‐B hepatitis (NANBH). Prior to therapy, serum HCV‐RNA w

Quantitative analysis of antibodies to h
Quantitative analysis of antibodies to hepatitis C virus during interferon-α therapy
✍ Nobukazu Yuki; Norio Hayashi; Hideki Hagiwara; Tetsuo Takehara; Kazuhiro Katayam 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 598 KB

W e quantified IgG antibodies to structural (core) and nonstructural (C100-3) hepatitis C virus proteins in 42 patients with chronic hepatitis C treated with a 6-mo course of interferon-a. Sera were drawn before and at the end of therapy and also 6 mo after therapy withdrawal; they were stored for l

Absence of hepatitis B virus precore mut
Absence of hepatitis B virus precore mutants in patients with chronic hepatitis B responding to interferon-α
✍ Jianye Xu; David Brown; Tim Harrison; Yue Lin; Geoffrey Dusheiko 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 614 KB

Precore defective HBV mutants may gradually prevail because of immune selection and explain spontaneous seroconversion from HBeAg to anti-HBe in HBV carriers. We have analyzed whether the presence of precore HBV mutants is a determinant of responsiveness to interferon-a therapy. Fifteen carriers (ni